Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...
The Food and Drug Administration (FDA) has approved a 420mg dosage strength of Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
Our country’s top breast cancer specialists declared Enhertu to be one of the top three priorities for unfunded drugs in New Zealand and the clinical trials for it have generated a level of excitement ...